Please login to the form below

Not currently logged in
Email:
Password:

UCB appoints Peter Theil head of non-clinical development

He joins the Belgium pharma company from Genentech

Peter Theil has joined UCB as vice president, head of non-clinical development for UCB's New Medicines research arm.

He joins the Belgium pharma company from Genentech, where he was head of early development, pharmacokinetic/pharmacodynamics sciences.

At UCB he will be part of New Medicine's leadership team and will be based in Braine, Belgium.

UCB said Theil's scientific knowledge, organisational and leadership skills would invaluable in continuing it unique emphasis and success in developing both small and large molecules.

Peter is the second new member of the New Medicines leadership team, following the recent appointment of Duncan McHale, who joined UCB as VP head of global exploratory development.

McHale moved to the company from AstraZeneca, where he was held the role of head of projects, VP personalised medicine and biomarkers.

28th November 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics